Dr Sarah Maloney
MBBS, MM (Clin Epi), FRACP, PhD, Medical Oncologist
Languages spoken
English
Overview
Clinical interests in gastrointestinal (GI) and respiratory cancers.
Dr Maloney is a medical oncologist and an early career translational researcher, having completed her training at Royal North Shore, St Vincent’s, and Liverpool hospital in 2020.
Dr Maloney is currently employed as a locum staff specialist at Royal North Shore and a visiting medical officer at North Shore Private Hospital and GenesisCare. Following her college exams she completed a Masters of Medicine (Clinical Epidemiology) in 2018. In 2024 Dr Maloney completed her translational PhD with the Bill Walsh Lab in the Kolling Institute, University of Sydney titled ‘The identification and evaluation of predictive and prognostic biomarkers in order to personalise treatment pathways for patients diagnosed with pancreatic cancer’. This research is focused on proteomic and transcriptomic analyses of endoscopic ultrasound biopsy and surgical tissue in patients with early pancreatic cancer.
Dr Maloney is an active member of Australian Gastro-Intestinal Trials Group (AGITG), Australian New Zealand Gynaecological group (ANZGOG) and a member of the AGITG Translational Research sub-committee. Dr Maloney is the co-chair of the NEO-IMPACT trial, a national co operative led trial.
Awards
- 2023 PemOla Grant – AGITG, PanKind, Co-investigator $297,000
- 2020 Cancer Research Network travel scholarship $1,000
- 2020 Primary investigator, Sydney Vital, ‘Research scholar’ award $10,000
- 2019 Primary investigator, Sydney Vital, ‘Research scholar’ award $10,000
- 2019-2023 Pancreatic Cancer Scholarship, Sydney Vital, $35,000 p.a, University of Sydney
Professional memberships
- 2023 – Current: European society of medical oncology (ESMO)
- 2018 – Current: Australasian Gastro-intestinal trials Group (AGITG)
- 2017 – Current: Australia and New Zealand Gynaecological Oncology Group (ANZGOG)
- 2017 – Current: Clinical oncology society of Australia (COSA)
- 2017 – Current: Medical Oncology group of Australia (MOGA)
Publications
- Byeon, S., du Toit‐Thompson, T., Hipperson, L., Maloney, S., Wenzel, R., Gill, A. J., ... & Sahni, S. (2024). Serum and tissue metallome of pancreatic ductal adenocarcinoma. Cancer Science, 115(5), 1446-1458.
- Maloney, S., Clarke, S. J., Sahni, S., Hudson, A., Colvin, E., Mittal, A., ... & Pavlakis, N. (2023). The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 149(14), 13437-13450.
- Maloney, S., Pavlakis, N., Itchins, M., Arena, J., Mittal, A., Hudson, A., ... & Clarke, S. J. (2023). The prognostic and predictive role of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) as biomarkers in resected pancreatic cancer. Journal of Clinical Medicine, 12(5), 1989.
- Sahni, S., Nahm, C., Ahadi, M. S., Sioson, L., Byeon, S., Chou, A., ... & Mittal, A. (2023). Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy. Cancer Medicine, 12(17), 18050-18061.
- Eshmuminov, D., Aminjonov, B., Palm, R. F., Malleo, G., Schmocker, R. K., Abdallah, R., ... & Lehmann, K. (2023). FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis and systematic review. Annals of surgical oncology, 30(7), 4417-4428.
- Maloney, S., Itchins, M., Arena, J., Sahni, S., Howell, V. M., Hayes, S. A., ... & Pavlakis, N. (2021). Optimal upfront treatment in surgically resectable pancreatic cancer candidates: a high-volume center retrospective analysis. Journal of Clinical Medicine, 10(12), 2700.
- Sahni, S., Krisp, C., Molloy, M. P., Nahm, C., Maloney, S., Gillson, J., ... & Mittal, A. (2020). PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression. Biochimica et Biophysica Acta (BBA)-General Subjects, 1864(11), 129682.
- Sahni, S., Nahm, C., Krisp, C., Molloy, M. P., Mehta, S., Maloney, S., ... & Mittal, A. (2020). Identification of novel biomarkers in pancreatic tumor tissue to predict response to neoadjuvant chemotherapy. Frontiers in oncology, 10, 237.
- Sahni, S., Pandya, A. R., Hadden, W. J., Nahm, C. B., Maloney, S., Cook, V., ... & Mittal, A. (2021). A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma. International Journal of Cancer, 148(6), 1508-1518.